Pharmacies and drug shortages
When FDA determines that certain manufactured drugs are in shortage, who’s there for you? Who fills the gaps?… (Read the rest)
End Drug Shortages Act intro’d in Congress
The legislation would expand the sources the FDA may use to declare drug shortages. read more →
FDA tirzepatide ‘reconsideration’ period extended
FDA agreed to extend until December 19 a final report on tirzepatide availability to the court. read more →
NPR hits the GLP-1 nail on the head
A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right. read more →
CALL TO ACTION: Tell FDA to deny drugmakers’ request
Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →
APC to FDA: Just say no to Lilly
This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →
California BOP sends proposed compounding regs to comment period
The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →
Checking in on the post-Chevron fallout
What’s happened in the world of federal regulation since the end of Chevron? read more →
Welcome to our newest Bronze-level Corporate Patron, Noom! read more →
When FDA determines that certain manufactured drugs are in shortage, who’s there for you? Who fills the gaps?… (Read the rest)
CONTACT US
E-mail: info@a4pc.org
Phone: (281) 933-8400
Fax: (281) 495-0602
Mailing: Alliance for Pharmacy Compounding
100 Daingerfield Road, Ste. 100
Alexandria, VA 22314
APC is committed to addressing any concerns or complaints within one business day. Please send them — and, of course, any compliments — to info@a4pc.org.
THE APC FAMILY